Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, Other, SGLT2i Aug 17 | 2023Zealand Q2 ’23 Earnings; TheracosBio Partners with SmithRx for Brenzavvy AccessPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Aug 15 | 2023Insulet Files Lawsuit Against EOFlow; Amazon Pharmacy Launches $35 Insulin Coupon; Welldoc Receives 510(k) Clearance for Connected Insulin Dosing Data; Dario Partners with PlanSourcePurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Aug 14 | 2023Lilly Completes Acquisition of Sigilon and Versanis; Galectin and Nemaura Q2 ‘23 Earnings; August CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 11 | 2023Novo Q2 ’23 London Earnings; Akero Q2 ’23 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 10 | 2023Senseonics and Dario Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 10 | 2023Novo Nordisk Q2 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Other Aug 09 | 2023Terns Announces Positive Topline Ph2a NASH Data; Ionis Q2 ’23 EarningsPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 09 | 2023Insulet, Xeris, Madrigal, and Bayer Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Aug 08 | 2023Lilly Up Big Following Q2 ’23 Results and SELECT Data ReadoutPurchase Blast
$599
Posted in: GLP-1RA, Other Aug 08 | 2023Novo and Lilly Win with Positive SELECT CVOT Topline ResultsPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery Aug 07 | 2023MannKind and Viatris Q2 ’23 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 04 | 2023Tandem, Lexicon, and Amgen Q2 ‘23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Other Aug 03 | 2023Alnylam and Regeneron Q2 ’23 Earnings; Ionis and Novartis Partner for New Lp(a) Therapy; NeuroBo Receives IRB Approval for Ph2a DA-1241 Study in NASHPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 02 | 2023Lilly Initiates Additional Ph3 Orforglipron Trial; Mounjaro Label Update; Vertex, Amarin, and Intercept Q2 ‘23 Earnings; Glenmark Receives ANDA Approval for 2.5mg and 5mg Saxagliptin; Dario Introduces GLP-1RA Obesity Program; Tandem Initiates Sigi Patch Pump TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other Aug 01 | 2023Altimmune Initiates Ph2b Pemvidutide NASH Trial; Pfizer, Esperion, and Merck Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 01 | 2023Afon to Launch Non-Invasive Blood Glucose Sensor in 2024; DEKA ACE Pump Receives 510(k) Clearance; Novo Nordisk Launches Wegovy in Germany; Ionis Completes CARDIO-TTRansform EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Other Jul 28 | 2023Lilly Completes Tirzepatide Obesity Trials; Teladoc, Viking, and Roche Q2 ‘23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jul 25 | 2023Wegovy Label Update; Jardiance Receives EMPA-KIDNEY Approval in EU; Glucotrack Announces Positive Implantable CGM Data; Thane Wettig Succeeds Enrique Conterno as Fibrogen CEOPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
